Lineage Cell Therapeutics Inc. (LCTX) PT Raised to $3 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LCTX Hot Sheet
Price: $1.03 +1.98%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy raised the price target on Lineage Cell Therapeutics Inc. (NYSE: LCTX) to $3.00 (from $1.50) while maintaining a Buy rating.
You May Also Be Interested In
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
- Pfizer (PFE) PT Raised to $40 at Argus
- Zimmer Biomet (ZBH) PT Raised to $125 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
